Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Resmed ( (RMD) ) is now available.
On July 28, 2025, Resmed announced the resignation of Bobby Ghoshal, their Chief Commercial Officer for the residential care software business, effective August 1, 2025. Ghoshal is leaving to become the Chief Operating Officer at a software company in a non-competitive industry, which may impact Resmed’s operations and industry positioning.
The most recent analyst rating on (RMD) stock is a Buy with a $240.00 price target. To see the full list of analyst forecasts on Resmed stock, see the RMD Stock Forecast page.
Spark’s Take on RMD Stock
According to Spark, TipRanks’ AI Analyst, RMD is a Outperform.
ResMed’s overall strong financial performance and positive earnings call sentiment are the most significant factors driving its stock score. While technical analysis shows bullish momentum, caution is advised as the stock approaches overbought levels. The valuation is moderate, reflecting a fair market price.
To see Spark’s full report on RMD stock, click here.
More about Resmed
Average Trading Volume: 884,845
Technical Sentiment Signal: Buy
Current Market Cap: $39.87B
See more insights into RMD stock on TipRanks’ Stock Analysis page.